Perrigo Receives Final Approval From FDA For Polyethylene Glycol 3350
The OTC product will be marketed under store brand labels and is indicated for the treatment of occasional constipation
Perrigo has received final approval from the FDA for its Abbreviated New Drug Application for over-the-counter Polyethylene Glycol 3350, Powder for Solution. Perrigo is expecting to begin shipping immediately.
Reportedly, the product will be marketed under store brand labels and is comparable to Schering-Plough HealthCare Products' Miralax, indicated for the treatment of occasional constipation.
Joseph Papa, chairman and CEO of Perrigo, said: “It is investments like this that help save OTC healthcare consumers more than an estimated $1billion annually when compared to the higher priced national brands."
Perrigo is a global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products.
Related Insight
Suppliers Directory
Investigator Location Services - Instant Access to Experienced Clinical Investigators
Investigator Location Services, Inc. (ILS), is the largest study broker with instant access to over 20,000 experienced clinical research investigators in the US and Canada in all medical specialties and practice settings. Our site provides a center for all clinical research and clinical trial personnel solutions.
Suppliers
Unilabs York Bioanalytical Solutions - Bioanalytical and Biomarker Specialists
Unilabs York Bioanalytical Solutions is a specialist provider of bioanalytical and biomarker analyses to pharmaceutical and biotech companies, supporting development of small and large molecule therapeutics, from discovery through to post-marketing.
Suppliers
Spectrum Chemical – Manufacturers and Distributors of Fine Chemicals & Laboratory Products
Founded in 1971, Spectrum Chemical offers the largest selection of monograph chemicals for drug, dietary supplements, functional foods and personal care products available from a single source.
Production & Manufacturing > Fine & Speciality Chemicals > Suppliers
Ferro Pfanstiehl Laboratories – Capture Your Vision
For more than 40 years, Ferro Pfanstiehl Laboratories, Inc., (FPL) a wholly-owned subsidiary of Ferro Corporation (NYSE: FOE), manufactures clinical and commercial quantities of active pharmaceutical ingredients (APIs), highly potent or highly cytotoxic active pharmaceutical ingredients (HPAPIs), advanced intermediates, and other small molecule new chemical entities (NCEs).
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Make time for science with the Rocket
Published by Genevac
White Papers
DXA Services
Published by CoreLab Partners
White Papers
Polymeric Nanofibers, Nanofibrous Layers, Nanofiber Yarns and Nanoparticles
Published by Phenom World
White Papers
Set-up Reduction in Biotech: When Every Minute Counts
Published by TBM Consulting Group
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.